NEW YORK – Lunit on Wednesday said it has partnered with the Society for Immunotherapy of Cancer (SITC) to offer its artificial intelligence (AI)-based Lunit SCOPE IO platform to advance cancer immunotherapy research.
Lunit SCOPE IO uses AI for quantitative immune phenotyping and tumor microenvironment (TME) analysis from H&E whole slide images. Lunit SCOPE IO can identify different immune cells such as tumor-infiltrating lymphocytes, macrophages, endothelial cells, and others; and perform quantitative immune phenotyping to identify inflamed, excluded, and desert phenotypes.
In the collaboration with SITC, academic and nonprofit researchers who are SITC members can use the Lunit SCOPE IO to analyze histologic features from H&E whole slide images, characterize the immune landscape of tumors, and identify biomarkers of immunotherapy response. SITC member researchers can submit applications for their studies to be part of the program, which Lunit and SITC expect to begin this summer.
"Through our partnership with SITC, we are enabling researchers to harness Lunit SCOPE IO's advanced AI capabilities for a deeper understanding of the tumor microenvironment," Lunit CEO Brandon Suh said in a statement.